keyword
MENU ▼
Read by QxMD icon Read
search

Bisphosphonates

keyword
https://www.readbyqxmd.com/read/28443172/does-discontinuing-teriparatide-treatment-and-replacing-it-with-bisphosphonate-maintain-the-volume-of-the-bone-fusion-mass-after-lumbar-posterolateral-fusion-in-women-with-postmenopausal-osteoporosis
#1
Seiji Ohtori, Sumihisa Orita, Kazuyo Yamauchi, Yawara Eguchi, Yasuchika Aoki, Junichi Nakamura, Miyako Suzuki, Gou Kubota, Kazuhide Inage, Yasuhiro Shiga, Koki Abe, Kazuki Fujimoto, Hirohito Kanamoto, Masahiro Inoue, Hideyuki Kinoshita, Takeo Furuya, Masao Koda
STUDY DESIGN: Retrospective case series. PURPOSE: The purpose of this study was to determine whether discontinuing teriparatide treatment and replacing it with bisphosphonate treatment maintains the volume of the fusion mass after posterolateral fusion (PLF) in women with postmenopausal osteoporosis. OVERVIEW OF LITERATURE: Clinical data support the efficacy of parathyroid hormone (PTH) for lumbar PLF. However, the use of PTH is limited to 2 years...
April 2017: Asian Spine Journal
https://www.readbyqxmd.com/read/28441214/the-osteo-odonto-keratoprosthesis
#2
Mehran Zarei-Ghanavati, Venkata Avadhanam, Alfonso Vasquez Perez, Christopher Liu
PURPOSE OF REVIEW: To describe the practice of and recent developments in the osteo-odonto-keratoprosthesis. RECENT FINDINGS: Formal psychological assessment and support have been described. A sub-aqua system for fashioning the osteo-odonto-keratoprosthesis lamina; adoption of thicker laminae; use of bisphosphonate drugs; advances in laminar imaging; and use of bone augmentation and bone morphogenetic protein have been described for prevention, detection, and management of laminar resorption...
April 24, 2017: Current Opinion in Ophthalmology
https://www.readbyqxmd.com/read/28432640/osteoporosis-bone-mineral-density-and-ckd-mbd-treatment-considerations
#3
REVIEW
Jordi Bover, Lucía Bailone, Víctor López-Báez, Silvia Benito, Paola Ciceri, Andrea Galassi, Mario Cozzolino
Osteoporosis and chronic kidney disease (CKD) have both independently important potential impact on bone health. A significant number of patients with CKD stages 3a-5D have been shown to have low bone mineral density (BMD), leading to a strikingly elevated risk of fractures (mainly hip fractures) and higher associated morbidity and mortality. Mechanical properties of bone beyond age and menopausal status are additionally affected by intrinsic uremic factors. Therefore, we review in this article not only general concepts of osteoporosis and related consequences, but also the diagnostic and therapeutic implications of low BMD and bone fractures in CKD, beyond increased vascular calcification...
April 21, 2017: Journal of Nephrology
https://www.readbyqxmd.com/read/28432595/what-animal-models-have-taught-us-about-the-safety-and-efficacy-of-bisphosphonates-in-chronic-kidney-disease
#4
REVIEW
Matthew R Allen, Mohammad W Aref
PURPOSE OF REVIEW: Bisphosphonates (BPs) have long been the gold-standard anti-remodeling treatment for numerous metabolic bone diseases. Since these drugs are excreted unmetabolized through the kidney, they are not recommended for individuals with compromised kidney function due to concerns of kidney and bone toxicity. The goal of this paper is to summarize the preclinical BP work in models of kidney disease with particular focus on the bone, kidney, and vasculature. RECENT FINDINGS: Summative data exists showing positive effects on bone and vascular calcifications with minimal evidence for bone or kidney toxicity in animal models...
April 21, 2017: Current Osteoporosis Reports
https://www.readbyqxmd.com/read/28432501/high-scale-yield-of-nano-hydroxyapatite-through-combination-of-mechanical-activation-and-chemical-dispersion
#5
Xueling Gao, Chunchu Dai, Weiwei Liu, Yumei Liu, Ru Shen, Xiaotong Zheng, Ke Duan, Jie Weng, Shuxin Qu
The aim of this study is to develop a simple, convenient and effective approach to synthesize nano-sized hydroxyapatite (nano-HA) at high-scale yield. Nano-HA was wet synthesized in the presence or absence of alendronate sodium (ALN), one of bisphosphonates for anti-osteoporotic. Then aged and washed nano-HA precipitate was directly treated by mechanical activation combined with the chemical dispersion of ALN to prevent the agglomeration of nano-HA. ALN acted not only as a chemical dispersant but also as an orthopedic drug...
June 2017: Journal of Materials Science. Materials in Medicine
https://www.readbyqxmd.com/read/28431581/sacroiliitis-mimics-a-case-report-and-review-of-the-literature
#6
Maria J Antonelli, Marina Magrey
BACKGROUND: Radiographic sacroiliitis is the hallmark of ankylosing spondylitis (AS), and detection of acute sacroiliitis is pivotal for early diagnosis of AS. Although radiographic sacroiliitis is a distinguishing feature of AS, sacroiliitis can be seen in a variety of other disease entities. CASE PRESENTATION: We present an interesting case of sacroiliitis in a patient with Paget disease; the patient presented with inflammatory back pain which was treated with bisphosphonate...
April 22, 2017: BMC Musculoskeletal Disorders
https://www.readbyqxmd.com/read/28429555/management-of-mineral-and-bone-disorders-in-renal-transplant-recipients
#7
Matthew J Damasiewicz, Peter R Ebeling
The management of post-transplantation bone disease is a complex problem that remains under-appreciated in clinical practice. In these patients, pre-existing metabolic bone disorder is further impacted by the use of immunosuppressive medications (glucocorticoids and calcineurin-inhibitors), variable post-transplantation renal allograft function and post-transplantation diabetes mellitus. The treatment of post-transplantation bone loss should begin pre-transplantation. All patients active on transplant waiting lists should be screened for bone disease...
March 2017: Nephrology
https://www.readbyqxmd.com/read/28425086/the-clinical-benefits-of-denosumab-for-prophylaxis-of-steroid-induced-osteoporosis-in-patients-with-pulmonary-disease
#8
Shigeo Ishiguro, Kentaro Ito, Shigenori Nakagawa, Osamu Hataji, Akihiro Sudo
Previous reports demonstrated that bone density decreased rapidly during the initial few months of steroid therapy and continued decreasing at a rate of 2 to 4% annually. Our data indicates that denosumab can also play a role in the treatment of osteoporosis in the steroid-taking population. INTRODUCTION: Respiratory physicians are often faced with the dilemma that long-term steroid use will deteriorate bone mineral density and quality. Previous reports demonstrated that bone density decreased 8 to 12% during the initial few months of steroid therapy then continued decreasing at a rate of 2 to 4% annually...
December 2017: Archives of Osteoporosis
https://www.readbyqxmd.com/read/28425085/uk-clinical-guideline-for-the-prevention-and-treatment-of-osteoporosis
#9
J Compston, A Cooper, C Cooper, N Gittoes, C Gregson, N Harvey, S Hope, J A Kanis, E V McCloskey, K E S Poole, D M Reid, P Selby, F Thompson, A Thurston, N Vine
INTRODUCTION: In 2008, the UK National Osteoporosis Guideline Group (NOGG) produced a guideline on the prevention and treatment of osteoporosis, with an update in 2013. This paper presents a major update of the guideline, the scope of which is to review the assessment and management of osteoporosis and the prevention of fragility fractures in postmenopausal women and men age 50 years or over. METHODS: Where available, systematic reviews, meta-analyses and randomised controlled trials were used to provide the evidence base...
December 2017: Archives of Osteoporosis
https://www.readbyqxmd.com/read/28416991/can-denosumab-be-a-substitute-competitor-or-complement-to-bisphosphonates
#10
REVIEW
Su Young Kim, Hwoe Gyeong Ok, Christof Birkenmaier, Kyung Hoon Kim
Osteoblasts, originating from mesenchymal cells, make the receptor activator of the nuclear factor kappa B ligand (RANKL) and osteoprotegerin (OPG) in order to control differentiation of activated osteoclasts, originating from hematopoietic stem cells. When the RANKL binds to the RANK of the pre-osteoclasts or mature osteoclasts, bone resorption increases. On the contrary, when OPG binds to the RANK, bone resorption decreases. Denosumab (AMG 162), like OPG (a decoy receptor), binds to the RANKL, and reduces binding between the RANK and the RANKL resulting in inhibition of osteoclastogenesis and reduction of bone resorption...
April 2017: Korean Journal of Pain
https://www.readbyqxmd.com/read/28416363/-adequacy-of-treatment-for-osteoporosis-in-primary-prevention-quantitative-and-qualitative-study
#11
Cristina Vedia Urgell, Mireia Massot Mesquida, Roser Valles Fernandez, Juan Antonio Garcia Vicente, Alicia Franzi Siso, Laura Muñoz Ortiz, Laia Vilaró Jaques, Maite Bosch Peligero
OBJECTIVE: Quantitative study: To assess the prevalence of inadequacy of treatment for osteoporosis in primary prevention (OPP) in women aged 60-74years. Qualitative study: To evaluate the diagnostic and treatment criteria of the OPP and it's variability in primary care physicians (PC) and specialists. MATERIAL AND METHODS: Quantitative study: observational, cross-sectional and retrospective study. POPULATION: women aged 60-74years with active treatment for OPP (n=424) in May 2012...
April 14, 2017: Atencion Primaria
https://www.readbyqxmd.com/read/28416300/pyrophosphate-supplementation-prevents-chronic-and-acute-calcification-in-abcc6-deficient-mice
#12
Viola Pomozi, Christopher Brampton, Koen van de Wetering, Janna Zoll, Bianca Calio, Kevin Pham, Jesse B Owens, Joel Marh, Stefan Moisyadi, András Váradi, Ludovic Martin, Carolin Bauer, Jeanette Erdmann, Zouhair Aherrahrou, Olivier Le Saux
Soft tissue calcification occurs in several common acquired pathologies, such as diabetes and hypercholesterolemia, or can result from genetic disorders. ABCC6, a transmembrane transporter primarily expressed in liver and kidneys, initiates a molecular pathway inhibiting ectopic calcification. ABCC6 facilitates the cellular efflux of ATP, which is rapidly converted into pyrophosphate (PPi), a major calcification inhibitor. Heritable mutations in ABCC6 underlie the incurable calcification disorder pseudoxanthoma elasticum and some cases of generalized arterial calcification of infancy...
April 14, 2017: American Journal of Pathology
https://www.readbyqxmd.com/read/28413771/management-of-aromatase-inhibitor-associated-bone-loss-aibl-in-postmenopausal-women-with-hormone-sensitive-breast-cancer-joint-position-statement-of-the-iof-cabs-ects-ieg-esceo-ims-and-siog
#13
REVIEW
Peyman Hadji, Matti S Aapro, Jean-Jacques Body, Michael Gnant, Maria Luisa Brandi, Jean Yves Reginster, M Carola Zillikens, Claus-C Glüer, Tobie de Villiers, Rod Baber, G David Roodman, Cyrus Cooper, Bente Langdahl, Santiago Palacios, John Kanis, Nasser Al-Daghri, Xavier Nogues, Erik Fink Eriksen, Andreas Kurth, Rene Rizzoli, Robert E Coleman
BACKGROUND: Several guidelines have been reported for bone-directed treatment in women with early breast cancer (EBC) for averting fractures, particularly during aromatase inhibitor (AI) therapy. Recently, a number of studies on additional fracture related risk factors, new treatment options as well as real world studies demonstrating a much higher fracture rate than suggested by randomized clinical controlled trials (RCTs). Therefore, this updated algorithm was developed to better assess fracture risk and direct treatment as a position statement of several interdisciplinary cancer and bone societies involved in the management of AI-associated bone loss (AIBL)...
June 2017: Journal of Bone Oncology
https://www.readbyqxmd.com/read/28413541/clival-giant-cell-tumor-a-rare-case-report-and-review-of-literature-with-respect-to-current-line-of-management
#14
Mohana Rao Patibandla, Amit Kumar Thotakura, Marabathina Nageswara Rao, Gokul Chowdary Addagada, Manisha Chowdary Nukavarapu, Manas Kumar Panigrahi, Shantiveer Uppin, Sundaram Challa, Srinivas Dandamudi
Giant-cell tumor (GCT) involving the skull base is rare. Sphenoid bone is the most commonly involved bone followed by petrous temporal bone. Histopathology and radiological features of these lesions are similar to GCT involving bone elsewhere. Unlike other sites, skull base is not an ideal site for the radical surgery. Hence adjuvant treatment has pivotal role. Radiation therapy with intensity-modulated radiation therapy, stereotactic radiosurgery or chemotherapy with adriamycin are promising as described in some case reports...
January 2017: Asian Journal of Neurosurgery
https://www.readbyqxmd.com/read/28413362/bone-loss-in-hiv-infection
#15
Caitlin A Moran, M Neale Weitzmann, Ighovwerha Ofotokun
Human immunodeficiency virus (HIV) infection is an established risk factor for low bone mineral density (BMD) and subsequent fracture, and treatment with combination antiretroviral therapy (cART) leads to additional BMD loss, particularly in the first 1-2 years of therapy. The prevalence of low BMD and fragility fracture is expected to increase as the HIV-infected population ages with successful treatment with cART. Mechanisms of bone loss in the setting of HIV infection are likely multifactorial, and include viral, host, and immune effects, as well as direct and indirect effects of cART, particularly tenofovir disoproxil fumarate (TDF) and the protease inhibitors (PIs)...
March 2017: Current Treatment Options in Infectious Diseases
https://www.readbyqxmd.com/read/28410753/retrospective-review-of-patients-with-atypical-bisphosphonate-related-proximal-femoral-fractures
#16
H K Phillips, S J Harrison, H Akrawi, S A Sidhom
INTRODUCTION: Patients may be at an increased risk of atypical proximal femoral fractures with prolonged bisphosphonate use. PATIENTS AND METHODS: This was a retrospective review of patients who sustained a subtrochanteric fracture of the femur in our department between April 2009 and March 2014. The radiographs were reviewed for features of atypical femoral fractures as described by the American Society of Bone Mineral Research. RESULTS: 185 patients were coded according to the National Hip Fracture Database as having sustained a subtrochanteric fracture of the femur...
April 4, 2017: Injury
https://www.readbyqxmd.com/read/28409215/high-and-pointed-type-of-femoral-localized-reaction-frequently-extends-to-complete-and-incomplete-atypical-femoral-fracture-in-patients-with-autoimmune-diseases-on-long-term-glucocorticoids-and-bisphosphonates
#17
H Sato, N Kondo, T Nakatsue, Y Wada, J Fujisawa, J J Kazama, T Kuroda, Y Suzuki, M Nakano, N Endo, I Narita
Once a localized reaction (beaking) was detected, discontinuation of bisphosphonates (BPs) and switching to vitamin D supplementation or teriparatide therapy effectively improved its shape. When the localized reaction was high, of the pointed type, and/or accompanied by prodromal pain, the risks of complete and incomplete atypical femoral fracture increased and consideration of prophylactic fixation for such patients was required. INTRODUCTION: Femoral localized reaction (localized periosteal thickening of the lateral cortex, beaking) is reported to precede atypical femoral fractures (AFFs) and to develop in 8-10% of patients with autoimmune diseases taking BPs and glucocorticoids...
April 13, 2017: Osteoporosis International
https://www.readbyqxmd.com/read/28408275/bisphosphonates-for-treatment-of-complex-regional-pain-syndrome-type-1-a-systematic-literature-review-and-meta-analysis-of-randomized-controlled-trials-versus-placebo
#18
Maxime Chevreau, Xavier Romand, Philippe Gaudin, Robert Juvin, Athan Baillet
OBJECTIVES: Complex Regional Pain Syndrome Type 1 is a severely disabling pain syndrome with no definite established treatment. We have performed a systematic literature review and meta-analysis of all randomized controlled trials to assess the benefit of bisphosphonates on pain and function in patients with Complex Regional Pain Syndrome Type 1. METHODS: A systematic literature search was performed in the Medline, Embase and Cochrane databases. Two authors selected independently blinded randomized trials comparing bisphosphonates to placebo on short-term (J30 to J40) and medium term pain (M2-M3), safety and function in patients with CRPS 1...
April 10, 2017: Joint, Bone, Spine: Revue du Rhumatisme
https://www.readbyqxmd.com/read/28407986/intravenous-bisphosphonate-therapy-does-not-thicken-cementum-or-change-periodontal-ligaments-of-cancer-patients
#19
Mariana de Pauli Paglioni, Wagner Gomes Silva, Juliana Pereira, César Augusto Migliorati, Marcio Ajudarte Lopes, Oslei Paes de Almeida, Mario Fernando Goes, Ana Carolina Prado Ribeiro, Thais Bianca Brandão, Alan Roger Santos-Silva
OBJECTIVE: To test the hypothesis that intravenous (IV) bisphosphonate (BP) therapy thickens or alters the micromorphology of cementum and periodontal ligament (PDL) in cancer patients. STUDY DESIGN: Thirty-two teeth extracted from 24 cancer patients and separated into test (patients who have undergone IV BP therapy, n = 16) and control (patients naive to BP therapy, n = 16) groups were studied. Cementum thickness was measured in 3 different areas of the dental root with polarized light microscopy...
May 2017: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
https://www.readbyqxmd.com/read/28405825/use-of-bisphosphonate-might-be-important-to-improve-bone-mineral-density-in-patients-with-rheumatoid-arthritis-even-under-tight-control-the-tomorrow-study
#20
Masahiro Tada, Kentaro Inui, Yuko Sugioka, Kenji Mamoto, Tadashi Okano, Shohei Anno, Tatsuya Koike
Although patients with rheumatoid arthritis (RA) are prone to osteoporosis, tight control of disease activity might have a positive effect on bone metabolism. We aimed to determine whether bisphosphonate use is still important to improve bone mineral density (BMD) in RA patients whose disease activity was tightly controlled and the dose of glucocorticoid was reduced. This study was a sub-analysis of the 10-year prospective cohort TOtal Management Of Risk factors in Rheumatoid arthritis patients to lOWer morbidity and mortality: the TOMORROW which started from 2010...
April 12, 2017: Rheumatology International
keyword
keyword
1525
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"